T1	Participants 94 161	younger patients with nonacute promyelocytic acute myeloid leukemia
T2	Participants 194 259	genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA
T3	Participants 351 457	younger patients with nonacute promyelocytic acute myeloid leukemia and high-risk myelodysplastic syndrome
T4	Participants 537 576	1075 patients less than 60 years of age
T5	Participants 788 869	NPM1 mutations (n = 592), CEBPA mutations (n = 423), and MN1 expression (n = 195)
T6	Participants 1329 1359	patients with lower MN1 levels
T7	Participants 1451 1481	patients with normal karyotype
